Ingrid L. Scully

5.2k total citations
44 papers, 1.5k citations indexed

About

Ingrid L. Scully is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Ingrid L. Scully has authored 44 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 22 papers in Infectious Diseases and 10 papers in Molecular Biology. Recurrent topics in Ingrid L. Scully's work include Pneumonia and Respiratory Infections (20 papers), Antimicrobial Resistance in Staphylococcus (18 papers) and Respiratory viral infections research (14 papers). Ingrid L. Scully is often cited by papers focused on Pneumonia and Respiratory Infections (20 papers), Antimicrobial Resistance in Staphylococcus (18 papers) and Respiratory viral infections research (14 papers). Ingrid L. Scully collaborates with scholars based in United States, United Kingdom and Japan. Ingrid L. Scully's co-authors include Annaliesa S. Anderson, Kathrin U. Jansen, William C. Gruber, Kathrin U. Jansen, Daniel A. Scott, Wendy Watson, Douglas Girgenti, David Cooper, Yekaterina Timofeyeva and Michael W. Pride and has published in prestigious journals such as Nature Communications, The Journal of Immunology and PLoS ONE.

In The Last Decade

Ingrid L. Scully

44 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ingrid L. Scully United States	22	688	588	419	291	285	44	1.5k
José Yuste Spain	27	1.3k 1.9×	293 0.5×	347 0.8×	368 1.3×	666 2.3×	88	2.1k
Sidorenko Sv Russia	21	602 0.9×	350 0.6×	324 0.8×	159 0.5×	373 1.3×	146	1.5k
Joseph Eiden United States	24	774 1.1×	569 1.0×	310 0.7×	95 0.3×	560 2.0×	56	2.5k
Christina von Hunolstein Italy	21	480 0.7×	314 0.5×	157 0.4×	545 1.9×	133 0.5×	62	1.3k
Yu‐Chia Hsieh Taiwan	21	664 1.0×	339 0.6×	133 0.3×	155 0.5×	202 0.7×	71	1.2k
Paula Mölling Sweden	25	897 1.3×	359 0.6×	336 0.8×	228 0.8×	602 2.1×	74	1.5k
Nelianne J. Verkaik Netherlands	22	369 0.5×	947 1.6×	614 1.5×	215 0.7×	213 0.7×	51	1.5k
Birgitta Henriques Normark Sweden	21	1.2k 1.7×	553 0.9×	293 0.7×	516 1.8×	442 1.6×	32	2.2k
Corné P. de Vogel Netherlands	18	332 0.5×	791 1.3×	466 1.1×	143 0.5×	197 0.7×	23	1.1k
Már Kristjánsson Iceland	19	390 0.6×	604 1.0×	229 0.5×	235 0.8×	90 0.3×	36	1.2k

Countries citing papers authored by Ingrid L. Scully

Since Specialization

Citations

This map shows the geographic impact of Ingrid L. Scully's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid L. Scully with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid L. Scully more than expected).

Fields of papers citing papers by Ingrid L. Scully

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid L. Scully. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid L. Scully. The network helps show where Ingrid L. Scully may publish in the future.

Co-authorship network of co-authors of Ingrid L. Scully

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid L. Scully. A scholar is included among the top collaborators of Ingrid L. Scully based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid L. Scully. Ingrid L. Scully is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Branche, Angela R, Mark J. Mulligan, Orlando Puente, et al.. (2025). A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults. Vaccines. 13(4). 383–383. 3 indexed citations

Haranaka, Miwa, Joon Young Song, Kuo‐Chin Huang, et al.. (2024). A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 42(5). 1071–1077. 6 indexed citations

Senders, Shelly, Nicola P. Klein, Allison Thompson, et al.. (2024). A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. The Pediatric Infectious Disease Journal. 43(6). 596–603. 21 indexed citations

Dutta, Kaushik, Ingrid L. Scully, Mark S. Kleven, et al.. (2023). Identification of a Novel Keto Sugar Component in Streptococcus pneumoniae Serotype 12F Capsular Polysaccharide and Impact on Vaccine Immunogenicity. The Journal of Immunology. 210(6). 764–773. 1 indexed citations

Kanevsky, Isis, Naveen Surendran, Wendy Watson, et al.. (2023). Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age. Vaccine. 41(45). 6625–6629. 3 indexed citations

Li, Hao, Michelle M. Kuttel, Neil Ravenscroft, et al.. (2022). Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A. Vaccine. 40(33). 4872–4880. 24 indexed citations

Essink, Brandon, James T. Peterson, Kari Yacisin, et al.. (2021). A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age. Human Vaccines & Immunotherapeutics. 17(8). 2691–2699. 2 indexed citations

Klein, Nicola P., Paula Peyrani, Kari Yacisin, et al.. (2021). A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 39(38). 5428–5435. 53 indexed citations

Fitzpatrick, David, Daniel A. Scott, Ingrid L. Scully, et al.. (2021). A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Human Vaccines & Immunotherapeutics. 17(7). 2249–2256. 9 indexed citations

10.

Haranaka, Miwa, James Baber, Yoichiro Ogama, et al.. (2021). A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications. 12(1). 7105–7105. 23 indexed citations

11.

Cannon, Kevin, Charles Elder, Daniel A. Scott, et al.. (2021). A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 39(51). 7494–7502. 48 indexed citations

12.

Anderson, Annaliesa S., et al.. (2020). Vaccination against Nosocomial Infections in Elderly Adults. PubMed. 43. 193–217. 5 indexed citations

13.

Essink, Brandon, Charu Sabharwal, Xia Xu, et al.. (2020). 3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older. Open Forum Infectious Diseases. 7(Supplement_1). S2–S2. 10 indexed citations

14.

Absalon, Judith, Nathan Segall, Stan L. Block, et al.. (2020). Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. The Lancet Infectious Diseases. 21(2). 263–274. 89 indexed citations

15.

Thompson, Allison, Joseph M. Severs, Ingrid L. Scully, et al.. (2019). Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 37(42). 6201–6207. 77 indexed citations

16.

Dupont, Christopher D., Ingrid L. Scully, Brinda Monian, et al.. (2018). Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response. mSphere. 3(4). 16 indexed citations

17.

Jia, Bin, Lisa K. McNeil, Christopher D. Dupont, et al.. (2017). Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires. PLoS ONE. 12(9). e0183738–e0183738. 10 indexed citations

18.

Dayan, Gustavo H., Naglaa Mohamed, Ingrid L. Scully, et al.. (2016). Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention. Expert Review of Vaccines. 15(11). 1373–1392. 115 indexed citations

19.

Marshall, Helen, Peter Richmond, Michael D. Nissen, et al.. (2015). Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in Australia. The Pediatric Infectious Disease Journal. 34(8). 831–838. 16 indexed citations

20.

Timofeyeva, Yekaterina, Ingrid L. Scully, & Annaliesa S. Anderson. (2013). Immunofluorescence Microscopy for the Detection of Surface Antigens in Methicillin-Resistant Staphylococcus aureus (MRSA). Methods in molecular biology. 1085. 85–95. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact